Tag: psoriasis

1. Guselkumab, an anti-interleukin-23 antibody, produced better responses in patients with moderate to severe plaque psoriasis than standard anti-TNF alpha therapy.  Evidence Rating Level: 1 (Excellent) Study Rundown: Interleukin-23 promotes inflammation and is expressed at high levels in psoriasis. Guselkumab is a monoclonal antibody which targets interleukin-23 and inhibits its effects....
1. Using the Physician Global Assessment (PGA), patients with acne or psoriasis recorded significant improvement in disease severity at 3-month follow-up. 2. Incorporating the PGA into billing sheets was a feasible method for seamless transition into clinical practice with an observed 100% physician compliance after follow-up. Evidence Rating Level: 2...
1. Treatment with brodalumab was shown to be safe and efficacious in patients with psoriatic arthritis or who previously failed treatment with biologic therapy.  Evidence Rating Level: 2 (Good) Study Rundown: Psoriasis is a chronic inflammatory skin disease that classically presents with itchy red lesions with a silvery scale....
Originally published by Harvard Health. What Is It? Psoriasis is a chronic skin disorder that causes scaling and inflammation. Psoriasis may develop as a result of an abnormality in the body's immune system. The immune system normally fights infection and allergic reactions. Psoriasis probably has a genetic component. Nearly half of patients have family...
1. Psoriasis severity was associated with an increased likelihood of uncontrolled hypertension. Evidence Rating Level: 2 (Good) Study Rundown: Psoriasis is a common chronic inflammatory disease in which changes in cell turnover cause the formation of thick scaly plaques on the skin. Previous studies have demonstrated increased risk for...
1. The use of 120mg ixekizumab in a phase-III, open-label extension (OLE) trial showed improved Psoriasis Area and Severity Index (PASI) outcomes in patients with chronic plaque psoriasis. 2. Ixekizumab was not associated with major cardiac events or deaths in this study. Evidence Rating Level: 2 (Good)            Study Rundown:...
1. A history of hypertension for 6 or more years was linked with an increased risk of psoriasis in US women.  2. Women with regular β-blocker usage were at higher risk of psoriasis than those who had never used β-blockers.  Evidence Rating Level: 2 (Good)  Study Rundown: Psoriasis is a systemic disease...